STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRAX
  4. [8-K] Praxis Precision Medicines, Inc. Reports Material Event

FDA Breakthrough Therapy nod for Praxis (PRAX) seizure drug elsunersen

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Praxis Precision Medicines reported that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for elsunersen (PRAX-222), an antisense oligonucleotide being developed to treat seizures associated with SCN2A developmental and epileptic encephalopathy caused by gain-of-function SCN2A variants.

This designation is intended to enable expedited development and regulatory review for therapies that treat serious conditions and show preliminary clinical evidence of substantial improvement over existing treatments. The decision was supported by positive topline results from the EMBRAVE Part A trial, a randomized, sham-controlled Phase 1/2 study in nine pediatric patients aged 2–12 years with early-seizure-onset SCN2A-DEE.

Positive

  • None.

Negative

  • None.

Insights

FDA Breakthrough Therapy status could speed elsunersen’s path if future data stay supportive.

The FDA’s Breakthrough Therapy Designation for elsunersen (PRAX-222) is a notable regulatory milestone. This status is reserved for drugs treating serious conditions where early clinical data suggest substantial improvement on clinically meaningful endpoints versus existing options.

The designation is based on positive topline data from the EMBRAVE Part A Phase 1/2 trial in nine children aged 2–12 with early-onset SCN2A-DEE. While early and in a small population, these results were sufficient for FDA to grant expedited development and review features.

Future value will hinge on how subsequent phases of EMBRAVE and other studies read out and whether elsunersen can maintain or improve upon the preliminary efficacy and safety signals that supported this designation.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Pediatric patients in EMBRAVE Part A 9 patients Randomized, sham-controlled Phase 1/2 trial of elsunersen in SCN2A-DEE
Patient age range 2–12 years Children enrolled in EMBRAVE Part A SCN2A-DEE trial
Trial phase Phase 1/2 EMBRAVE Part A study of elsunersen in SCN2A-DEE
Breakthrough Therapy Designation regulatory
"the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (“BTD”) for elsunersen"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
antisense oligonucleotide medical
"elsunersen (PRAX-222), an antisense oligonucleotide for the treatment of seizures"
An antisense oligonucleotide is a small piece of synthetic genetic material designed to attach to specific molecules in the body’s cells, effectively blocking or modifying how genes are expressed. This technology is important because it can be used to develop targeted treatments for certain diseases, which may influence the value of biotech companies and the broader healthcare sector. Its development reflects advances in personalized medicine and gene-based therapies.
SCN2A Developmental and Epileptic Encephalopathy medical
"for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (“DEE”)"
randomized, sham-controlled technical
"EMBRAVE Part A trial, a randomized, sham-controlled Phase 1/2 study evaluating ascending doses"
topline results financial
"The BTD for elsunersen was supported by positive topline results from the EMBRAVE Part A trial"
Topline results are the initial, high-level summary of the most important outcomes from an event such as a clinical trial or a company reporting period — for a drug study this means whether the main goals were met and basic safety info, and for a company it often means headline revenue and profit figures. Investors care because these summaries act like a headline that quickly signals whether prospects have improved or worsened, often driving immediate market reactions before the full details are released.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
FALSE000168954800016895482026-06-222026-06-22

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2026
PRAXIS PRECISION MEDICINES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-39620
47-5195942
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

Praxis Precision Medicines, Inc.
99 High Street, 30th Floor
Boston, Massachusetts 02110
(Address of principal executive offices, including zip code)
(617) 300-8460
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trade
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share PRAX The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 


Item 8.01. Other Events.
On June 22, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (“BTD”) for elsunersen (PRAX-222), an antisense oligonucleotide for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (“DEE”) caused by Gain of Function variants in SCN2A. The BTD enables expedited development and regulatory review for drugs that are intended to treat a serious condition, where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over existing therapies. The BTD for elsunersen was supported by positive topline results from the EMBRAVE Part A trial, a randomized, sham-controlled Phase 1/2 study evaluating ascending doses of elsunersen in nine pediatric patients aged 2–12 years with early-seizure-onset SCN2A-DEE.



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PRAXIS PRECISION MEDICINES, INC.
Date: June 22, 2026By: /s/ Marcio Souza
 Marcio Souza
 Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Praxis Precision Medicines (PRAX) announce regarding elsunersen?

Praxis Precision Medicines announced that the FDA granted Breakthrough Therapy Designation for elsunersen (PRAX-222). This status recognizes early evidence that the drug may substantially improve seizure outcomes in SCN2A developmental and epileptic encephalopathy compared with existing therapies.

What is FDA Breakthrough Therapy Designation for PRAX-222?

Breakthrough Therapy Designation is an FDA program to expedite development and review of drugs for serious conditions. For PRAX-222, it reflects preliminary clinical evidence that may show substantial improvement on clinically meaningful seizure endpoints over available treatments in SCN2A-DEE.

Which condition is Praxis’s elsunersen intended to treat?

Elsunersen is intended to treat seizures associated with SCN2A developmental and epileptic encephalopathy caused by gain-of-function SCN2A variants. This is a severe pediatric neurological disorder characterized by early-onset, difficult-to-control seizures and significant developmental impairment.

What clinical data supported the Breakthrough Therapy Designation for PRAX-222?

The designation was supported by positive topline results from EMBRAVE Part A, a randomized, sham-controlled Phase 1/2 trial. The study evaluated ascending doses of elsunersen in nine pediatric patients aged 2–12 years with early-seizure-onset SCN2A-DEE.

What is the EMBRAVE Part A trial mentioned by Praxis Precision Medicines?

EMBRAVE Part A is a randomized, sham-controlled Phase 1/2 clinical study of elsunersen. It tests ascending doses in nine children aged 2–12 years with early-seizure-onset SCN2A-DEE, generating the preliminary efficacy and safety data that underpinned FDA’s Breakthrough Therapy Designation.

Filing Exhibits & Attachments

3 documents

Other Documents